Summary: Hypertension is the most common risk factor for cardiovascular morbidity and mortality. In Poland, 11 million people suffer from hypertension. The level of blood pressure control is insufficient – it is 23–33%. According to the current guidelines, in most patients with hypertension, therapy should be started with a combination drug in the SPC formula (single pill combination – one tablet). This approach allows to achieve good blood pressure control in 60% of patients. The use of triple SPC allows to achieve good blood pressure control in 90% of patients. It is worth reaching for SPC preparations, because their use translates into greater adherence, persistence in therapy and a lower risk of treatment discontinuation. This in turn leads to greater optimization of the cardiovascular risk associated with hypertension. The availability of various SPC combinations allows for personalization of therapy. Hypertension often coexists with metabolic syndrome, hence it is worth reaching for SPC containing metabolically beneficial drugs, such as valsartan (the best-studied sartan in the cardiovascular continuum) and indapamide (an effective hypotensive drug with a favorable metabolic profile). This article discusses the benefits of using SPC valsartan + indapamide.